GE

MPI Research, Edge partner on brain hemorrhage therapies

Friday, April 6, 2012 09:57 AM

MPI Research, the world’s largest single-site preclinical CRO, and Edge Therapeutics, a hospital-focused biopharmaceutical company, will collaborate on preclinical and clinical testing of Edge's lead product candidates to advance life-saving therapies after brain hemorrhaging.

More... »

GE Healthcare acquires SeqWright, boosts Clarient unit

Wednesday, April 4, 2012 03:01 PM

GE Healthcare has acquired SeqWright, a provider of nucleic acid sequencing and other genomic services, adding complementary genomics capabilities to Clarient, a molecular diagnostics GE unit.

More... »

Amgen, AstraZeneca to develop and commercialize inflammation portfolio

Monday, April 2, 2012 04:38 PM

Amgen and AstraZeneca have agreed to jointly develop and commercialize five monoclonal antibodies from Amgen's clinical inflammation portfolio (AMG 139, AMG 157, AMG 181, AMG 557 and brodalumab (AMG 827)).

More... »

Compugen expands to California to develop mAb drug candidates

Monday, April 2, 2012 03:31 PM

Compugen Inc., a Canadian therapeutic product discovery company, has established new operations in South San Francisco, Calif., for the development of oncology and immunology monoclonal antibody (mAb) drug candidates against Compugen-discovered targets.

More... »

1000 Genomes Project data available on Amazon Cloud

Monday, April 2, 2012 02:51 PM

The world's largest set of data on human genetic variation — produced by the international 1000 Genomes Project — is now publicly available on the Amazon Web Services (AWS) cloud, the according to the National Institutes of Health (NIH).

More... »

Daiichi forms diabetes alliance with NGM Biopharma

Friday, March 30, 2012 03:07 PM

Tokyo-based Daiichi Sankyo has formed a partnership with San Francisco-based NGM Biopharmaceuticals to research and develop new treatments for diabetes.

More... »

Sanofi, Regeneron share results for lipid-lowering PCSK9 antibody

Tuesday, March 27, 2012 06:34 AM

Sanofi and Regeneron Pharmaceuticals have reported promising data from two phase II trials with SAR236553/REGN727—an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9).

More... »

Celtic launches $50 million antibody drug conjugates company

Monday, March 26, 2012 12:19 PM

Celtic Therapeutics Management, a global private equity firm focused on novel therapeutic product candidates, has announced a significant commitment to Antibody-Drug-Conjugate (ADC) products with the launch of a new Lausanne, Switzerland-based company, ADC Therapeutics Sarl.

More... »

iBio completes phase I trial of H1N1 vaccine

Friday, March 23, 2012 04:13 PM

Chicago-based biotech iBio has completed its first human trial of iBioLaunch-produced H1N1 influenza vaccine (HAC1) assessing safety, reactogenicity and immunogenicity.

More... »

Donald P. Rosen named CEO of ACR Image Metrix

Friday, March 23, 2012 03:21 PM

The American College of Radiology (ACR) has named medical imaging contract-research pioneer and distinguished physician, Donald P. Rosen, MD, CEO of ACR Image Metrix, an imaging CRO.

More... »